ClinicalTrials.Veeva

Menu

Inflammatory Response in Myocardial Infarction Evaluated by MRI and Biomarkers (RIFIFI)

Civil Hospices of Lyon logo

Civil Hospices of Lyon

Status

Completed

Conditions

Myocardial Infarction

Treatments

Biological: Blood samples
Other: MRI at D7

Study type

Interventional

Funder types

Other

Identifiers

NCT02823886
69HCL16_0130

Details and patient eligibility

About

An intense inflammatory reaction is triggered by the ischemic injury during myocardial infarction. The inflammatory processes involved are complex and haven't been explored in detail in human patients. This inflammatory response can increase myocardial damage following reperfusion, leading to adverse remodeling and adverse events (heart failure, sudden cardiac death).

Cardiac MRI can assess the size of myocardial infarction and many other parameters associated with myocardial injury: edema, hemorrhage, micro-vascular obstruction.

(However the association between biomarkers of inflammation and these imaging parameters is not known).

There is very little data correlating imaging markers of myocardial injury to the biokinetics of inflammation biomarkers.

In this study, the aim is to assess the relationship between the kinetics of specific inflammatory biomarkers (interleukin-1beta, interleukin 6, interleukin 17, Tumor Necrosis Factor (TNF)-alpha, C reactive protein (CRP), soluble toll-like receptor-2 (ST2), neutrophils) and imaging markers of injury measured by cardiac MRI at the acute phase in 20 acute mycardial infarction (AMI) patients.

Enrollment

21 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • All patients, aged over 18, without any legal protection measure,
  • Having a health coverage,
  • Presenting within 12 hours of the onset of chest pain,
  • Who have ST segment elevation ≥0.2 millivolt (mV) in two contiguous leads,
  • For whom the clinical decision was made to treat with percutaneous coronary intervention (PCI).
  • he culprit coronary artery has to be the left anterior descending (LAD) or the right coronary (RC)
  • The LAD or RC artery has to be occluded (TIMI flow grade 0-1) at the time of admission coronary angiography.
  • Preliminary oral informed consent followed by signed informed consent as soon as possible
  • Final TIMI ≥ 2

Exclusion criteria

  • Female patients currently pregnant or women of childbearing age who were not using contraception (oral diagnosis).
  • Patients with cardiogenic shock
  • Patient in Cardiac arrest
  • History of Myocardial Infarction
  • Contre-indication to MRI : claustrophobia, pacemaker or cardiac defibrillator , eye metal body allergy to gadolinium
  • Patient with Atrial Fibrillation.
  • Patients with loss of consciousness or (Glasgow <14)
  • known renal insufficiency (either known creatinin clearance < 30 ml/min/1.73m² or current medical care for severe renal insufficiency)
  • Patients with any disorder associated with immunological dysfunction
  • Adult with legal protection measure

Trial design

Primary purpose

Prevention

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

21 participants in 1 patient group

STEMI patients
Experimental group
Treatment:
Other: MRI at D7
Biological: Blood samples

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems